Being a world leader in melanoma research, MIA participates in, and presents projects and discoveries, at international skin cancer and oncology conferences.

esmo-2022

September 2022

NeoPeLe: A Phase 2 Trial of Neoadjuvant Pembrolizumab Combined with Lenvatinib In Resectable Stage III Melanoma

Georgina V Long, Andrew Spillane, Thomas Pennington, Kerwin F Shannon, Jonathon R Stretch, Maria Gonzalez, Robyn PM Saw, Serigne Lo, Richard A Scolyer, Alexander M Menzies

To determine the the pathological response rate to 6 weeks of neoadjuvant pembrolizumab plus lenvatinib, and to determine the RECIST and metabolic response at week 6, the relapse free survival and to evaluate the effects on tumour tissue and peripheral blood.


September 2022

Histopathological Analysis of Neoadjuvant Sequential or Combination Targeted Therapy (TT) and anti-PD-1; Combined Analysis of NeoTrio and NeoCombi Clinical Trials

J. Braden, A.J. Potter, E. Paver, R Rawson, A M. Menzies, M.S. Carlino, G. Au-Yeung, R.P.M. Saw, A.J. Spillane, K.F. Shannon, T. E. Pennington, S. Ch’ng, D. E. Gyorki, J. Howle, D. Daneshvar, J.S. Wilmott, S. E. Lo, I.P. Silva, R.A. Scolyer, G.V. Long

To characterise key histopathological changes with neoadjuvant targeted therapy (TT), anti-PD-1 or combination and their association with pathological response.


September 2022

805P: Predicting recurrence-free survival for patients with stage II melanoma –a validated tool to guide selection for adjuvant systemic therapy

Alexander HR Varey, Mary-Ann El Sharouni, Julie Simon, Jeffrey E. Gershenwald, Georgina V. Long, Richard A. Scolyer, John F. Thompson, Serigne N. Lo

To develop a user-friendly externally validated tool for predicting relapse free survival (RFS) and overall survival (OS) in stage II melanoma patients (with or without sentinel node biopsy).


September 2022

850P: A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanoma

Amelia M Taylor, Claire Galea, Isabel Li, Alexander HR Varey, Kerwin Shannon, Sydney Ch’ng, Robyn PM Saw, Thomas Pennington, Jonathan Stretch, Andrew Spillane, Alexander C J van Akkooi, Ines P da Silva, Matteo S Carlino, Richard A Scolyer, Georgina V Long, Serigne Lo, Alexander M Menzies

To develop a web app to guide discussions about risk of recurrence with or without therapy at baseline and during a patient’s treatment journey.


September 2022

809P: Outcomes of patients with resected stage III/IV acral or mucosal melanoma treated with adjuvant anti-PD-1 therapy

Sarah Jacques, Janet McKeown, Piyush Grover, Benjamin Park, Anne Zaremba, FlorentinaDimitriou, Mohamad Farid, Kenjiro Namikawa, Megan Mooradian, Joanna Placzke, Clare Allayous, InderjitMehmi, Danielle Depalo, Alexandre Wicky, Julia Schwarze, Yasuhiro Nakamura, SeverineRoy, Alex Menzies, SerigneLo, Matteo Carlino

Determine risk of recurrence of resected acral melanomas (AM) and mucosal melanomas (MM) following adjuvant anti-PD-1, and quantify the effect of adjuvant anti-PD-1 in AM and MM compared to a historical matched cohort.


September 2022

838P: Patterns of response/progressive disease and management following progressive disease with anti PD 1 therapy in patients with advanced cutaneous Squamous Cell Carcinoma

J. Mo, S. Bohne, C. Gaudy Marqueste, N. Della Marta , L. Festino, C. Chen, S. Lo, J. Park, P. Ascierto, R. Ladwa, W. Xu, J J. Grob, A. Hauschild. A. Menzies, GV. Long, M. Carlino, I. Pires da Silva

For advanced cutaneous Squamous Cell Carcinoma evaluate site specific patterns of response to anti PD-(L)1 and study the management following progression to anti PD-(L)1.


September 2022

824P: Patterns of response/progression and management following progressive disease with anti PD –(L)1 therapy in patients with advanced Merkel Cell Carcinoma

J. Mo, A. Zaremba, J. Inderjeeth , P. El Zenaity, A. Li, A. Wicky, N. Della Marta, C. Gaudy Marqueste, S. Bohne, L. Festino, C. Chen, S. Lo, A. Guminski, O. Michielin, W. Xu, C. Lebbe, S. Sandhu, L. Zimmer, M. Carlino, I. Pires da Silva

For Merkel Cell Carcinoma evaluate site specific patterns of response of  to anti PD-(L)1 and study the management following progression to anti PD-(L)1.

iap-2022

Posters will be published closer to the time of IAP 2022.

ASCO 2022

June 2022

Neoadjuvant dabrafenib and trametinib (D+T) for stage III melanoma – long-term results from the NeoCombi trial

Alexander M Menzies, Robyn P M Saw, Serigne Lo, Maria Gonzalez, Sydney Ch’ng, Omgo E Nieweg, Kerwin F Shannon, Peter M Ferguson, Jenny Lee, Helen Rizos, Robert V Rawson, Jonathan R Stretch, John F Thompson, Louise Emmett, Rony Kapoor, Andrew J Spillane, Richard A Scolyer, Georgina V Long

A report of 5-year outcomes from the NeoCombi trial (NCT01972347),  for patients with resectable stage III melanoma.


June 2022

A biomarker guided Bayesian response-adaptive phase II trial for metastatic melanoma – The Personalised Immunotherapy Platform (PIP) Trial Design 

Serigne N. Lo, Tuba N. Gide, Maria Gonzalez, Ines P. da Silva, Alexander M. Menzies, Matteo S. Carlino, Richard A. Scolyer,
Stephane Heritier, James S. Wilmott, Georgina V. Long

To assess RECIST objective response rate (ORR) to 5 novel anti-PD-1 drug combinations as first and subsequent line therapy.


June 2022

Preferences for Adjuvant Immunotherapy in Patients with Resected Stage III Melanoma: A Discrete Choice Experiment (DCE)

Ann Livingstone, Alexander M Menzies, Kirsten Howard, Martin R Stockler, Rachael L Morton

A study to quantify stage III resected melanoma patient preferences and trade-offs for adjuvant immunotherapy.


June 2022

Efficacy and safety of “second adjuvant” therapy with BRAF/MEK inhibitors after resection of recurrent melanoma following adjuvant PD-1-based immunotherapy

Amelia M. Taylor, Claire Galea, Serigne N. Lo, Florentia Dimitriou, Sarah Jacques, Clara Allayous, Hui-Ling Yeoh, Julia M. Ressler, Katharina C. Kähler, Lucia Festino, Julia K. Schwarze, Alexandre M. Wicky, Joanna Placzke, Douglas B. Johnson, Lisa Zimmer, Celeste Lebbe, Reinhard Dummer, Matteo S. Carlino, Georgina V. Long, Alexander M. Menzies

A study to explore the efficacy and safety of ‘second adjuvant’ BRAF/MEKiin BRAFV600 patients who recurred despite adjuvant immunotherapy.


June 2022

VEGF inhibitors (VEGFi) activity in liver metastases (mets) regardless of primary cancer type – meta-analysis and systematic review

Inês Pires da Silva, Serigne Lo, Jordan Conway, Richard Scolyer, Matteo S. Carlino, Alexander M. Menzies, Georgina V. Long

A study to assess the efficacy of VEGFi in liver metastases utilizing randomized-controlled clinical trials (RCTs) testing the efficacy of VEGFi, regardless of primary cancer site.


June 2022

Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity – A multicentre case series

Harvey, C;  Nahar, K; Lo, S; Ahmed, T; Farag, S; Yousaf, N; Young, K; Tas, L; Eggink, A; Blank, C; Thomas, A; McQuade, J; Schilling, B; Johnson, DB; Martin-Huertas, R; Arance, A; Lee, J; Zimmer, L; Long, GV; Menzies, AM

A study to estimate the prevalence of patients with GI toxicity who are both steroid and IFX refractory (MIA cohort), describe the investigation and management IRIGItox, assess the efficacy of post IFX interventions and assess survival outcomes stratified by post IFX intervention.

8 April 2022

Molecular analysis finds excision margin width predictive of recurrence in acral melanoma

Grace H. Attrill, Teresa A. Bailey, Trina Lum, Jordan W. Conway, Georgina V. Long, James S. Wilmott, Richard A. Scolyer

This study aims to determine whether molecular markers can detect molecularly abnormal but histologically normal cells beyond the tumor margin, and whether such cells are associated with recurrence in acral melanoma.

16 Sept 2021

1042P: Anti-PD1 (PD1) monotherapy or in combination with ipilimumab (IPI) after BRAF/MEK inhibitors (BRAF/MEKi) in BRAF mutant metastatic melanoma (MM) patients (pts) (PDF)

Ines Pires da Silva, Danny Zakria, Tasnia Ahmed, Claudia Trojaniello, Florentia Dimitriou, Clara Allayous, Camille Gerard, Lisa Zimmer, Serigne Lo, Olivier Michielin, Celeste Lebbe, Joanna Mangana, Paolo Ascierto, Douglas B. Johnson, Matteo S. Carlino, Alexander M. Menzies, Georgina V. Long

The AIMS of this study are:
1. To determine the efficacy (objective response rare [ORR], PFS and OS) and safety of PD1 vs IPI+PD1 after BRAF/MEKi.
2. To identify the subgroup of patients with >3 years OS with PD1+/-IPI after BRAF/MEKi.



16 Sept 2021

Efficacy of checkpoint inhibitors in acral melanoma (PDF)

Prachi Bhave, Tasnia Ahmed, Alexander Shoushtari, Anne Zaremba, Judith Versluis, Joanna Mangana, Michael Weichenthal, Lu Si, Thierry Lesimple, Caroline Robert, Claudia Trojaniello, Alexandre Wicky, Richard Heywood, Lena Tran, Kathleen Batty, Anna Stansfeld, Celeste Lebbe, Julia Katharina Schwarze, Meghan Mooradian, Matteo S Carlino

A study to examine the efficacy of combination checkpoint inhibitors (CPIs) in acral melanoma (AM) compared to single agent CPI, and determine if primary AM site influences patient outcomes.

Patterns and management of progression on 1st line ipilimumab combined with anti-PD-1 (IPI+PD1) in metastatic melanoma (MM) patients (PDF)

Ines Pires da Silva, Judith M. Versluis, Tasnia Ahmed, Douglas Buckner Johnson, Jennifer Soon, Clara Allayous, Camille L. Gerard, Joanna Mangana, Oliver Klein, Lisa Zimmer, Caroline Robert, Maria Grazia Vitale, Hui-Ling Yeoh, Olivier Michielin, Celeste Lebbe, Shahneen K. Sandhu, Christian U. Blank, Matteo S. Carlino, Alexander M. Menzies, Georgina V. Long

Research from MIA’s Medical Oncologist Dr Ines Silva and her team focussed on patients whose disease progressed after first being treated with combination immunotherapy – drugs that stimulate immune cells to fight cancer. Although around half of these patients are still alive five years after starting treatment, the majority of patients will progress and may require further treatment.


IL 6 blockade for prophylaxis and management of immune related adverse events in cancer immunotherapy (PDF)

Florentia Dimitriou, Sabrina Hogan, Phil F. Cheng, Reinhard Dummer, Alexander M. Menzies, Georgina V. Long

Treatment of melanoma with immunotherapy can be lifesaving; however, it can also be complicated by significant side effects as the activated immune system cells may attack healthy cells as well. Immune cells communicate by producing small proteins, called ‘cytokines’, which co-ordinate the body’s response against inflammation. Medical Oncologist Dr Florentia Dimitriou and colleagues identified a cytokine, known as IL-6, which is increased in many inflammatory conditions.


Efficacy of Adjuvant Radiotherapy in Recurrent Melanoma after Adjuvant Immunotherapy (PDF)

Prachi Bhave, Angela Hong, Rebecca Johnson, Alexander M Menzies, Georgina V Long, Joanna Mangana, Douglas B Johnson, Zeynep Eroglu, Ozgecan Dulgar, Hui-Ling Yeoh, Andrew M Haydon, Georg Lodde, Elisabeth Livingstone, Adnan Khattak, Katharina Kahler, Axel Hauschild, Wei Wang, Matteo S Carlino

In an era where immunotherapy is now often given to reduce recurrence after surgery, Medical Oncologist Dr Prachi Bhave and colleagues at MIA investigated whether adjuvant radiotherapy is still effective in reducing melanoma recurrence. The study found that radiotherapy significantly reduced the risk of melanoma returning in nearby lymph nodes, and therefore continues to have a role in some patients whose melanoma has returned despite receiving immunotherapy after surgery.


Management of resected stage III/IV melanoma with adjuvant immunotherapy (PDF)

Rebecca Johnson, Victoria Atkinson, Prachi Bhave, Alison M. Weppler, Geoffrey David Peters, Afaf Abed, Megan Lyle, Muhammad Adnan Khattak, Andrew Mark Haydon, Matteo S. Carlino, Shahneen Kaur Sandhu, Georgina V. Long, Alexander M. Menzies

Immunotherapy after surgery for Stage III melanoma has become the standard treatment approach. This research aimed to understand who is being treated with immunotherapy across Australia, how effective the treatment was, and the variety of treatment options that are implemented if the melanoma recurs.

Poster title

Authors

Description